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Abstract  
Benign hepatosteatosis, affected by lipid uptake, de novo lipogenesis and fatty acid (FA) 
oxidation, progresses to non-alcoholic steatohepatitis (NASH) on stress and inflammation. 
A key macronutrient proposed to increase hepatosteatosis and NASH risk is fructose, 
whose excessive intake causes intestinal barrier deterioration and endotoxemia. However, 
how fructose triggers these alterations and their role in hepatosteatosis and NASH 
pathogenesis remain unknown. By preventing fructose and endoplasmic reticulum stress-
dependent barrier deterioration and subsequent endotoxemia using a chemical chaperon, 
activation of mucosal-regenerative gp130 signaling, administration of the YAP-induced 
matricellular protein CCN1 or expression of anti-microbial Reg3β peptide, we show that 
microbiota-derived Toll-like receptor (TLR) agonists promote hepatosteatosis without 
affecting fructose-1 phosphate (F1P) and cytosolic acetyl-CoA. TLR engagement triggers 
TNF production by liver macrophages to induce lipogenic enzymes that convert F1P and 
acetyl-CoA to FA in mouse and human hepatocytes.  
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Non-alcoholic steatohepatitis (NASH), a severe manifestation of non-alcoholic fatty liver 
disease (NAFLD) which affects 30% of adult Americans1, is a leading cause of liver failure, 
cirrhosis and cancer2. NAFLD starts as simple steatosis with little liver damage or fibrosis, 
whose progression to NASH depends on multiple parallel hits acting in concert with 
hepatosteatosis. The latter can be due to increased lipid import, enhanced de novo 
lipogenesis (DNL), or impaired β oxidation3. Proposed hits include gut-derived inflammatory 
signals and endoplasmic reticulum (ER) stress3–7. Hav ing  established a role for ER stress 
and TNF signaling in NASH pathogenesis8,9, we sought to unravel the role of gut-derived 
inflammatory signals linked to fructose-induced barrier deterioration. Fructose, whose US 
consumption had increased several thousand-fold, is a key macronutrient that may 
contribute to NASH development10. Fructose causes barrier deterioration through a 
heretofore unknown mechanism entailing downregulation of tight junction proteins (TJP) in 
animal subjects and pediatric patients11–13. Fructose also triggers dysbiosis14 and its 
metabolism by gut bacteria generates short chain fatty acids (SCFA)15, proposed to improve 
barrier function16,17. Unlike glucose, which is generated by hydrolysis of starch and is 
metabolically mobilized by the highly regulated enzyme glucokinase, fructose is 
phosphorylated by the constitutively active enzyme fructokinase (also known as 
ketohexokinase/KHK)18, that is particularly active in hepatocytes in which it stimulates DNL 
and hepatic fat deposition10,19. DNL depends on two key enzymes, acetyl CoA carboxylase 
(ACC) and fatty acid synthase (FAS), whose expression is induced by fructose20. Here we 
show that gut barrier deterioration and subsequent endotoxemia result in hepatic induction 
of ACC1 and FAS and other SREBP1-activated lipogenic genes to upregulate DNL without 
an effect on KHK-dependent fructose-1 phosphate (F1P) and cytosolic acetyl-CoA 
accumulation. Fructose-elicited endotoxemia activates Toll-like receptor (TLR) signaling in 
liver macrophages, whose blockade via myeloid-specific MyD88 ablation prevents TNF, 
ACC1 and FAS induction and attenuates hepatosteatosis. Conversely, addition of TNF to 
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cultured human hepatocytes enhances fructose conversion to lipids. Correspondingly, 
genetic and pharmacological manipulations that prevent ER stress-dependent fructose-
induced barrier deterioration and endotoxemia block fructose-stimulated DNL, 
hepatosteatosis and the onset of steatohepatitis and cancer.  
Results 
Fructose stimulates DNL and triggers hepatosteatosis, steatohepatitis and HCC  
Transgenic (Tg) MUP-uPA mice expressing high amounts of urokinase plasminogen 
activator (uPA) from a liver-specific promoter were used to establish a causal role for 
hepatocyte ER stress in NASH pathogenesis8. Although MUP-uPA mice older than 8 weeks 
kept on normal chow diet (NCD) do not display obvious hepatic abnormalities, when placed 
on energy-rich high fat diet (HFD) they manifest classical NASH signs within 3-4 months 
and progress to hepatocellular carcinoma (HCC) by 9-10 months. Prevention of hepatocyte 
ER stress blocks NASH development8 by inhibiting  IRE-1 dependent translation and 
subsequent activation of caspase-29. Induction of Caspase-2 mRNA requires TNF 
signaling, whose blockade also blocks NASH development8,9. The mechanism by which 
HFD induces TNF secretion by liver macrophages is unknown. We used the MUP-uPA 
model and parental BL6 mice to investigate whether fructose-induced DNL can elicit NASH 
and subsequent HCC development. Both MUP-uPA and BL6 mice were given isocaloric 
low-fat and carbohydrate-rich diets containing either fructose or cornstarch (CS), a polymer 
that is readily hydrolyzed to glucose. Whereas high fructose diet (HFrD) contains 10% CS 
and 60% fructose, the CS diet (CSD) derives 70% of its calories from CS. Although diet 
consumption was similar, HFrD, but not CSD, induced hepatosteatosis and increased liver 
triglycerides (TG) in both strains (Fig. 1a, b and Extended Data Fig. 1a-c). Steatohepatitis, 
ballooning degeneration and liver fibrosis were apparent in 6-month-old HFrD-fed MUP-uPA 
mice, but BL6 mice only showed benign steatosis. HFrD feeding did not cause adiposity 
and white adipose tissue (WAT) was somewhat smaller in HFrD-fed animals (Extended 
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Data Fig. 1d, e). HFrD feeding induced colon shortening, a sign of intestinal inflammation 
(Extended Data Fig. 1f) and caused more insulin resistance than CSD, as shown by 
glucose tolerance tests (GTT), while mildly decreasing energy expenditure in 6-month-old 
mice kept in metabolic cages, which did not differ in weight gain (Extended Data Fig. 1g-j). 
Consistent with insulin-resistance, non-fasting insulin was higher in HFrD-fed mice 
(Extended Data Fig. 1k). After 12 months, HFrD-fed MUP-uPA mice exhibited 3-fold more 
HCC nodules that were larger than those in CSD-fed mice, resulting in 10-fold higher tumor 
burden (Fig. 1c, d). HFrD also enhanced diethyl nitrosamine (DEN)-induced HCC in BL6 
mice, which do not develop cancer without it (Fig. 1e). Most tumors in HFrD-fed mice were 
poorly differentiated, steatotic HCCs (Extended Data Fig. 1l). 
The cytosolic pool of acetyl-CoA, needed to initiate DNL, was two-fold higher in HFrD- 
than CSD-fed MUP-uPA mice (Extended Data Fig. 2a). Prolonged HFrD consumption 
markedly upregulated hepatic mRNAs for SREBP1c (Srebf1), carbohydrate-responsive 
element-binding protein (ChREBP/Mixipl) and the SREBP1-regulated enzymes 
ACC1/Acaca and FAS/Fasn, while downregulating mRNAs coding for FA oxidizing 
enzymes (Fig. 2a and Extended Data Fig. 2b, c). Liver mRNAs for inflammatory cytokines 
and chemokines, including TNF, were elevated (Fig. 2b). Continuous HFrD feeding 
dramatically increased ACC1 and FAS amounts (Fig. 2c), and upregulated hepatic DNL, 
elevating C16:0 and C18:0 synthesis by 2-fold relative to CSD (Fig. 2d). Short-term (48-
hour) HFrD feeding, however, did not elevate FA synthesis in liver or jejunum, although it 
strongly increased F1P amounts in both tissues (Extended Data Fig. 2d-f). Inflammatory 
cytokines, chemokines, and lipogenic mRNAs, other than Acaca, were not induced and 
ACC1 protein was barely elevated after a 48-hour exposure (Extended Data Fig. 2g). 
Fructose-induced barrier deterioration and intestinal epithelial ER stress 
Although short term HFrD feeding did not alter intestinal permeability based on fecal 
albumin content and FITC-dextran translocation (Extended Data Fig. 2h), prolonged HFrD 
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feeding caused intestinal barrier deterioration (Fig.3a). Fecal albumin elevation, however, 
was prevented by treatment with an antibiotics (Abx) cocktail21 that reduces fecal bacteria 
by more than 99.5% . Prolonged HFrD feeding reduced TJP mRNAs coding for Tjp2, 
occludin, and different claudins (including seal-forming claudin 3) in large and small 
intestine (Fig. 3b, c). Although some of these effects, especially in colon, were reversed by 
Abx treatment, most downregulated jejunal TJP mRNAs remained suppressed and occludin 
and claudin 1 downregulation was only partially reversed (Extended Data Fig. 3a-c), 
Moreover, incubation of microbiota-free colonic organoids with 5-20 mM fructose decreased 
numerous TJP mRNAs (Fig. 3d). Il22 mRNA and some IL-22-induced antimicrobial protein 
(AMP) mRNAs (Lcn2, S100a9) were increased in colons of HFrD- fed mice (Extended Data 
Fig. 3d), presumably as an attempt at barrier restoration22, but Reg3b and Reg3g mRNAs 
were suppressed by HFrD-feeding. Abx treatment attenuated Il22, Lcn2, and S100a9 
mRNA induction. Previous studies demonstrated that colonic inflammation upregulates 
S100 mRNAs but downregulates Reg genes23. Administration of a 30% wt:vol fructose 
solution, accounting for 32% of daily caloric intake in NCD-fed BL6 mice, also reduced TJP 
mRNAs,  caused colonic shortening and increased FITC-dextran translocation (Extended 
Data Fig 3e, f). In contrast, a 30% sucrose drink did not reduce colon length or TJP mRNAs 
and barely increased ER stress markers (Extended Data Fig.3g-i). These results are 
consistent with the weaker effect of sucrose vs. fructose on hepatic steatosis24 
 
Colonic shortening is a sign of inflammation. To explore a plausible cause of mucosal 
inflammation, which can downregulate TJPs25, we posited that the fructose metabolite F1P 
interferes with N-glycosylation as previously documented in hereditary fructose 
intolerance26. Defective N-glycosylation triggers ER stress, a source of mucosal 
inflammation27, and impairs TJP transport and assembly28. Indeed, HFrD feeding strongly 
induced the ER stress markers/unfolded protein response (UPR) effectors Chop, 
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Bip/Grp78, and spliced Xbp1 and increased eIF2α phosphorylation in intestinal mucosa 
along with elevated inflammatory markers (Fig. 3e). In vitro incubation of colonic organoids 
with fructose, but not glucose, also induced Chop and sXbp1 mRNAs and this was 
attenuated by glucose addition (Extended Data Fig. 3j), suggesting that interference with N-
glycosylation may be involved. To explore the role of F1P in this response we incubated 
organoids with the KHK inhibitor 420640. This abrogated Chop and sXbp1 mRNA induction 
by fructose and diminished the decrease in most TJP mRNAs (Extended Data Fig. 3k, l). A 
similar protective effect was seen upon organoid incubation with the chemical chaperon 
tauroursodeoxycholic acid (TUDCA) (Extended Data Fig. 3m), which reduces liver ER 
stress and steatosis in MUP-uPA mice8.  Importantly, TUDCA treatment of BL6 mice given 
a 30% fructose drink attenuated colonic shortening, reduced FITC-dextran translocation, 
inhibited ER stress marker induction and prevented TJP mRNA downregulation (Fig. 3f-h). 
HFrD induces liver inflammation and myeloid cell TLR signaling 
Exploratory transcriptomic analysis independently validated by immunoblot (IB) and RT-
PCR analyses revealed marked differences in expression of innate immunity- and 
inflammation- related genes between tumor-free 6-month-old CSD- and HFrD-fed livers 
(Fig. 4 a, b and Extended Data Fig. 4a, b). HCC nodules, however, exhibited fewer diet-
related transcriptomic changes, especially in HCC-related genes (Extended Data Fig. 4c,d), 
which were essentially identical to those upregulated in HFD-induced HCC29. HCC-specific 
genes were elevated in CSD- and HFrD-associated tumors from 9-month-old mice relative 
to non-tumor liver, further demonstrating that HFrD mainly altered hepatic pathophysiology 
prior to tumor onset. Gene ontology enrichment analysis of the non-tumor transcriptome 
revealed large changes in genes involved in response to wounding, wound healing, cell 
adhesion, innate immunity, and responses to molecules of bacterial origins (Extended Data 
Fig. 4e). IB analysis confirmed elevated TLR2 and 4, MyD88, NLRP3 and STAT3 
phosphorylation in HFrD-fed livers, changes that were abrogated by Abx treatment (Fig.4c).  
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Increased TLR2, TLR4, MyD88 and NLRP3 expression most likely took place in liver-
recruited macrophages. Accordingly, we ablated MyD88 in myeloid cells and examined the 
impact on HFrD-induced DNL controlling enzymes, inflammatory cytokines and 
hepatosteatosis. Although myeloid MyD88 ablation only inhibited Tnf, Il1β and Ccl2 mRNA 
induction with no effect on Ccl5 and Il6 mRNAs, it substantially decreased expression of 
DNL-related proteins and reduced hepatic TG accumulation in HFrD-fed mice (Fig. 4d-f).  
Consistent with elevated TLR expression and the protective effect of macrophage 
MyD88 ablation, prolonged HFrD feeding increased circulating endotoxin in MUP-uPA and 
BL6 mice, whereas Abx administration inhibited endotoxemia and attenuated HFrD-
stimulated liver tumorigenesis (Extended Data Fig. 5a, b). Abx treatment also blocked 
hepatosteatosis, TG accumulation and induction of DNL-related enzymes, inflammatory 
cytokines and chemokines (Extended Data Fig. 5c-g). Importantly, Abx treatment did not 
reduce liver F1P and had a marginal effect on cytosolic acetyl-CoA in HFrD-fed mice 
(Extended Data Fig. 5h, i), suggesting it does not affect fructolysis. Abx treatment, however, 
prevented HFrD-induced glucose intolerance and reduced non-fasting serum insulin without 
affecting body or WAT weight; it also reduced liver fibrosis and abrogated colon shortening 
(Extended Data Fig. 5j-n). 
All HFrD-elicited phenotypic changes, including hepatosteatosis and elevated DNL-
related enzymes, upregulation of innate immune proteins and inflammatory mediators and 
downregulation of TJP genes, were also observed in 6-month-old BL6 mice and were 
inhibited by Abx (Extended Data Fig. 6a-g). Thus, fructose-induced barrier deterioration and 
subsequent DNL and steatohepatitis are independent of genetic background or carcinogen-
induced genetic alterations. Fructose drink (30%) administration also enhanced 
hepatosteatosis and upregulated liver mRNAs encoding inflammatory chemokines, 
cytokines and DNL enzymes in BL6 mice (Extended Data Fig. 7a, b). Fructose drink 
consumption, however, increased body and WAT weight, rendering dissociation of its liver-
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specific effects from those caused by increased caloric intake and peripheral obesity 
somewhat difficult (Extended Data Fig. 7c). To mimic human Western diet that is rich in 
both fat and fructose and reduce the caloric contribution of fructose from 32% in the above 
experiment to 20.9% an amount equivalent to that consumed by the 95th percentile of 
American adolescents30, we placed BL6 mice on HFD composed of 59% fat, 15% protein 
and 26% carbohydrates, and either regular water or a 30% fructose drink. Despite its 
reduced overall caloric contribution, fructose still increased body, WAT and liver weight, 
augmented hepatosteatosis and induced liver mRNAs encoding inflammatory chemokines, 
cytokines and DNL enzymes, while downregulating TJP mRNAs and increasing FITC-
dextran translocation (Extended Data Fig. 7d-h). 
 
Barrier restoration inhibits DNL and prevents steatohepatitis 
Acute tight junction loss activates YAP and TAZ, closely related transcriptional activators 
that stimulate tissue repair31. Indeed, incubation of colonic organoids with fructose rapidly 
induced the YAP targets Ctgf and Ccne1 (Extended Data Fig. 8a). Mucosal Ctgf and Ccne1 
mRNAs were also upregulated in HFrD-fed mice, but this chronic response was attenuated 
relative to the acute response manifested by fructose-incubated organoids (Extended Data 
Fig. 8b). Ccne1 encodes the matricellular protein CCN1, whose administration promotes 
barrier repair via integrin-mediated IL-6 incuction32, whereas engagement of IL-6 signal 
transducer (IL6ST/gp130) promotes mucosal repair via STAT3 and YAP33. Congruently, 
IEC-specific expression of constitutively active gp130 variant (gp130Act)33 conferred partial 
resistance to fructose-induced TJP mRNA downregulation in organoids (Extended Data Fig. 
8c). IEC- specific gp130Act expression was even more effective in vivo, restoring Reg3b, 
Reg3g, Tjp mRNAs and claudin-1 and inhibiting HFrD-induced FITC-dextran translocation 
and endotoxemia (Extended Data Fig. 8d-h). Remarkably, MUP-uPA/gp130Act mice were 
resistant to fructose-induced hepatic tumorigenesis and failed to upregulate hepatic mRNAs 
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encoding inflammatory and lipogenic proteins (Fig. 5a, b). Liver DNL rates were lower in 
HFrD-fed MUP-uPA/gp130Act mice than in MUP-uPA mice (Fig. 5c), but F1P accumulation in 
either liver or jejunum was not reduced (Extended Data Fig. 8i), indicating that YAP and 
STAT3 activation does not decrease fructose uptake. Administration of recombinant CCN1 
was also protective, reversing fructose-induced colon-shortening and TJP mRNA 
downregulation and reducing fecal albumin (Extended Data Fig. 8j-l). Moreover, CCN1 
treatment inhibited fructose-stimulated DNL, hepatosteatosis, steatohepatitis and liver FAS 
expression without affecting body weight (Extended Data Fig. 8m-p). 
Reg3β, whose expression is suppressed by HFrD, is an AMP that targets gram-negative 
bacteria and may neutralize endotoxin34. Accordingly, transgenic Reg3β expression from 
the IEC-specific Villin promoter prevented HFrD-induced hepatosteatosis (Fig. 5d). The 
Reg3b transgene also prevented fructose induction of liver mRNAs for inflammatory 
cytokines and lipogenic enzymes without affecting body weight (Fig. 5e, f). Reg3β IEC 
expression reduced HFrD-induced endotoxemia, but the increase in circulating endotoxin in 
HFrD-fed wt animals was of low statistical significance (Extended Data Fig. 8q). 
Conversely, low-dose LPS administration for 3 months caused TG accumulation and 
upregulation of DNL- and inflammation-related mRNAs in both CSD-fed MUP-uPA and 
HFrD-fed MUP- uPA/gp130Act livers (Extended Data Fig. 9a-f), suggesting that circulating 
endotoxin triggers fatty liver disease. 
Sequencing of fecal microbial 16S rRNA gene amplicons confirmed that prolonged HFrD 
consumption caused mild dysbiosis in MUP-uPA mice, characterized by decreased α 
diversity (Extended Data Fig. 9g). β diversity analysis by PERMANOVA based on 
unweighted UniFrac distances revealed significant (pseudo-F statistic = 2.88, P < 0.001) 
clustering of fecal samples according to diet (Extended Data Fig. 9h). Fecal 16S 
sequencing on CSD- and HFrD-fed MUP-uPA/gp130Act mice showed that prolonged HFrD 
feeding also caused dysbiosis in this mouse strain (Extended Data Fig. 9i, j). 
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TNF stimulates fructose-driven lipogenesis 
We used primary hepatocyte cultures to examine whether TNF also stimulates fructose-
driven steatosis in human liver. Primary hepatocytes from healthy donors were left 
unstimulated or treated with either LPS or TNF and placed in sugar-free culture medium or 
medium containing 5 mM glucose or fructose for 48 hours, after which lipid droplet 
accumulation was assessed. Whereas glucose or fructose alone or together with LPS 
barely affected lipid droplet formation, TNF treatment strongly enhanced lipid droplet 
buildup in both fructose and glucose incubated hepatocytes (Fig. 6a, b). TNF, but not LPS, 
induced ACACA, FASN and SREBF1 mRNAs. 
Discussion           
Excessive fructose intake causes dysbiosis and TJP downregulation, resulting in 
intestinal barrier deterioration and low-grade endotoxemia11–13. Fructose consumption 
stimulates hepatosteatosis and when combined with other risk factors can cause 
steatohepatitis and even HCC. It is well established that fructose is a more effective inducer 
of hepatic DNL than glucose19,20. However, the exact mechanism by which fructose 
preferentially stimulates DNL, other than its KHK-dependent conversion to acetyl-CoA via 
fructolysis, remains obscure. In particular, the metabolic effects of fructose-induced barrier 
deterioration and endotoxemia have not been investigated. We now show that fructose-
induced endotoxemia, which can be prevented through transgenic gp130 and Reg3β 
expression or CCN1 administration, activates MyD88-mediated inflammatory signaling in 
liver myeloid cells, thus leading to TNF induction (Fig. 6c). We previously showed that TNF 
signaling via TNFR1 together with ER stress-activated IRE1 stimulates hepatosteatosis 
through caspase-2 mediated SREBP1 activation9. Accordingly, myeloid cell MyD88 
signaling is required for induction of the key lipogenic enzymes ACC1 and FAS in mouse 
liver and TNF treatment of cultured human hepatocytes greatly enhances lipid droplet 
buildup after incubation with either fructose or glucose, correlating with SREBF1, ACACA 
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and FASN mRNA induction. Of note, fructose-induced endotoxemia does not affect 
fructose uptake, its conversion to F1P and subsequent acetyl-CoA generation via 
fructolysis. These new insights to fructose-induced hepatic lipid accumulation suggest that 
fructose and other dietary factors that cause barrier deterioration contribute to the onset of 
steatohepatitis by stimulating net FA and TG accumulation in hepatocytes and also by 
decreasing mitochondrial β oxidation. 
Our results explain why fructose rather than glucose leads to barrier deterioration. 
Fructose is converted by KHK to F1P, a toxic metabolite whose accumulation in aldolase B 
deficient individuals interferes with protein N-glycosylation26. Defective N-glycosylation 
interferes with protein transport and secretion, thereby leading to ER stress and 
inflammation35. We show that HFrD, but not CSD, consumption induces ER stress in IEC 
and colonic inflammation. Fructose treatment of colonic organoids also triggers ER stress, 
which can be prevented by KHK inhibition. In addition to inflammation, ER stress also 
causes TJP downregulation27,28, increasing translocation of luminal microbial products and 
enhancing the hepatic inflammatory response. Accordingly, the chemical chaperon TUDCA, 
activation of mucosal-regenerative gp130 signaling or administration of CCN1 prevent 
fructose-induced TJP downregulation and endotoxemia, thus blocking subsequent 
stimulation of hepatic DNL and steatohepatitis (Fig.6c).Future studies will tell whether 
CCN1 and other agents, such as aryl hydrocarbon receptor agonists36, that stimulate 
mucosal healing can reduce NAFLD and NASH incidence in humans. Another potential 
preventative/therapeutic approach that deserves further consideration is endotoxin 
neutralization. Although our mouse model experiments, which employ high amounts of 
fructose, may not be immediately extended to humans, we suggest that barrier deterioration 
may only occur after continuous and excessive consumption of fructose and is probably 
influenced by various dietary and genetic factors or co-morbidities. Of note, the composition 
of the diet determines the relative contribution of DNL to hepatosteatosis, such that DNL 
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becomes more important when fat intake is low. Nonetheless, barrier decline has been 
described in various experimental models and in numerous liver diseases that entail hepatic 
fat accumulation and inflammation37,38. Thus, the finding that excessive fructose ingestion 
leads to hepatic fat accumulation through a pathway that involves barrier deterioration, 
endotoxemia, activation of myeloid cell MyD88 signaling and TNF secretion, and induction 
of lipogenic enzymes in hepatocytes, may be of relevance to several common liver 
diseases and metabolic disorders. 
Methods 
Mouse Studies 
MUP-uPA and gp130Act mice were described8,33 and were crossed to generate MUP-
uPA/gp130Act mice. C57BL/6 mice were purchased from Charles River Laboratories and 
Reg3bIEC transgenic mice in which the villin promoter drives Reg3b in intestinal epithelial cells 
(IEC) were generated at the University of Frankfurt. All experiments were conducted on 
adult males, whose age is specified in the Figure Legends and Method Details section. To 
induce HCC in BL6 mice, DEN (25 mg/kg) was injected intraperitoneally (i.p.) into 14-day-
old males. Mice were randomly placed on one of two isocaloric diets purchased from 
Research Diets Inc.: (a) control corn starch d iet  (CSD) in which 70% of calories are from 
corn starch, 10% from fat, and 20% from protein, totaling 4.1 kcal/g, or (b) high-fructose 
diet (HFrD) in which 60 % of calories are from fructose, 10% from corn starch, 10% from fat, 
and 20% from protein; 4.1 kcal/g. Both diets contain 4.7 gm % fiber. Mice were treated with 
antibiotics as described21,39. Mice were also given NCD or HFD as previously8 and allowed 
free access to either 30% fructose or sucrose in water solution or regular drinking water. 
Mice were given daily 250 mg/kg TUDCA or vehicle (PBS) i.p. injections for the last 10 
weeks of fructose drink exposure. All mice, unless indicated otherwise, were on the 
C57BL/6 background and group-housed (3-4 mice per cage) in filter-topped cages on 
autoclaved food and water at UCSD, according to NIH guidelines. All experiments were 
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performed using UCSD IACUC-approved protocols in accordance with UCSD and NIH 
guidelines and regulations. The Reg3bIEC experiments were performed at the University of 
Frankfurt in accordance with German law and regulations.                                                                                     
Human Hepatocyte Cultures 
                                                                                                                                                                                                   
    Donor livers rejected for transplantation were obtained via LifeSharing OPO as a part of Dr.T. 
Kisseleva’s research program. Donors with no history of alcohol abuse, low BMI (18-22), no liver 
fibrosis, no diabetes, minimal steatosis, and normal levels of ALT and AST were qualified as 
normal in this study conducted under IRB 171883XX (approved on 11/9/17). For hepatocyte 
isolation the livers were placed on top of an ice pan covered by a plastic bag and then a sterile 
field. Catheters were inserted into the major portal and/or hepatic vessels and the tissue was 
perfused with cold organ preservation solution or EMEM (Corning Cellgro cat # 15-010-CM) + 25 
mM HEPES (Corning Cellgro cat# 25-060-CI) to determine which vessels provide the most uniform 
tissue perfusion. This step also helps remove any remaining blood. The catheters were then 
secured into the vessels either by sutures or surgical grade glue. All remaining major vessels on 
the cut surfaces were closed with sutures or surgical grade glue. The liver tissue was then placed 
in a sterile plastic bag and connected to a peristaltic pump with flowrate dependent on the number 
of catheters and size of tissue. 
 
The bag containing the tissue was placed in a water bath at 38.5°C and the tissue was perfused 
with HBSS (without calcium and magnesium or phenol red) (Hyclone cat # SH30588.02) 
supplemented with 1.0 mM EGTA without recirculation for 10-20 min. The EGTA chelates calcium 
which leads to the separation of cell junctions and helps remove any residual blood. Finally, the 
liver specimen was perfused with EMEM containing 0.1 mg/ml of collagenase (VitaCyte cat# 001-
2030) and 0.02 mg/ml of protease (VitaCyte cat# 003-1000) which is recirculated as long as 
needed to complete the digestion (15-30 min total digestion time). Perfusion was stopped when the 
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liver tissue began to show fissures and separation from the liver capsule. The liver tissue was then 
removed from the plastic bag and placed in a sterile plastic beaker that contains warmed (37oC) 
DMEM supplemented with 5% FBS, 1% Sodium pyruvate, 1% antibiotic. The specimen was then 
gently dissociated with sterile scissors to release hepatocytes. The cell suspension was filtered 
through sterile nylon mesh covered funnels to remove cellular debris and clumps of undigested 
tissue. The above steps were repeated as many times as needed to obtain the maximum numbers 
of cells. Hepatocytes were isolated from other cell types in the suspension by low speed 
centrifugation at 80x g for 5 min at 18oC. The supernatant was decanted and saved (NPC 
fraction).The hepatocyte pellets were gently resuspended in a Percoll (Sigma # GE17-0891-09) 
gradient and centrifuged at 100x g for 10 minutes at 18oC.The supernatant was removed by 
aspiration and the pellets were saved and resuspended in warmed (37oC) DMEM and the 
centrifugation step was repeated. The supernatant was removed and the hepatocytes were 
resuspended in 4oC Hypothermosol FRS (BioLIfe Solutions # 101104) to make the Hepatocyte 
Stock. An aliquot of the Hepatocyte Stock (150 µl) was removed and placed in a 1.5ml Eppendorf 
tube, mixed with an equal volume of trypan blue and assessed by dye exclusion to determine cell 
viability and number using a hemocytometer. Cell viability was expressed as a percentage of the 
total cells counted (# of live cells/[# of live cells + # of dead cells] x 100 = % viable). Usually there 
were 515X106 total viable cells in the Hepatocyte Stock. An aliquot of 6X106 viable hepatocytes 
was removed from the hepatocyte stock and diluted with 5 volumes of ice cold EMEM. The aliquot 
was centrifuged at 100x g and 180C for 5 min. The supernatant was removed and the pellet was 
resuspended in 12 ml of Hepatocyte Plating Medium**. The hepatocytes were then seeded on a 
collagen coated 24 well plate and allowed to attach in a 370C, 5% CO2 incubator for 2-12 hours 
and then the medium is changed to serum free Hepatocyte Maintenance Medium. The remaining 
Hepatocyte Stock was allowed to settle at 4oC for 1-2 hours. The excess liquid was carefully 
removed from the bottle with care not to disturb the hepatocytes at the bottom. The cell suspension 
was then brought to a final concentration of 8 x 106 hepatocytes/ml using a solution of Cryostor 
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CS10 (BioLife Solutions # 210102) +DMSO+Fructose giving a final concentration of 10% DMSO + 
100 mM Fructose. The cell suspension was placed at 1.5ml/vial, into 2ml freezing vials and frozen 
in control rate freezer till used. 
*Hepatocyte Plating Medium: Williams’ E medium from Life Technologies (Cat. # A12176-01) 
containing 10mM HEPES, 2mM L-Glutamine, 10%FBS, 1X10-7M Dexamethasone, 1X10-7M 
Insulin and 1% Antibiotic/Antimycotic solution. **Hepatocyte Maintenance Medium = Hepatocyte 




Freshly collected liver tissues from MUP-uPA, MUP-uPA;gp130Act, Reg3bIEC and C57BL/6 
mice were fixed in 10% neutral-buffered formalin or 4% paraformaldehyde, embedded in 
paraffin, sectioned and stained with hematoxylin and eosin (H&E) and Sirius Red. For 
frozen-block preparation, tissues were embedded in Tissue-Tek OCT compound and 
stained with Oil Red O and H&E. For Oil Red O and Sirius Red analysis, multiple images 
were examined for each section. Representative images were captured on an upright 
light/fluorescent microscope (Zeiss) equipped with an AxioCam camera. 
Lipidomics 
Triacylglycerol (TAG) lipid species were measured as described40 with minor 
modifications. Briefly, freshly isolated liver samples were homogenized in one volume of 
phosphate buffered saline (PBS) (pH 7.4), and sonicated. Next, a BCA protein assay was 
performed and 25 µg of each liver sample aliquoted and utilized for lipid extraction. An 
internal standard mixture and CHCl3/methanol (2:1) mixture were added to each sample 
before being vortexed, mixed, sonicated, and centrifuged. Lipid-containing supernatants 
were removed and dried before being resuspended in H2O-saturated butanol and sonicated 
again. Methanol with 10 mM ammonium were added and the resuspended samples were 
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centrifuged and the supernatants were transferred to individual glass vials. Lipidomic 
determination was performed by liquid chromatography electrospray ionization tandem 
mass spectrometry (LC-MS) combined with a triple quadrupole mass spectrometer. Data 
were analyzed using Multiquant software v1.2 and TAG normalized to the total 
phosphatidylcholine (PC) levels of each sample. 
Indirect calorimetry 
Mice were placed into Comprehensive Lab Animal Monitoring System (CLAMS; 
Columbus Instruments) metabolic cages to adapt to their surroundings for 48 hours before 
study. Data from 3 light/dark cycles were used in the analysis. Rates of O2 consumption 
(VO2; ml/kg/hour) and CO2 production (VCO2) were continuously acquired. 
Immunoblotting and antibodies 
IB analysis was performed on tissue or cell lysates that were SDS-PAGE separated and 
transferred to nitrocellulose membranes. Blots were incubated with 5% (wt:vol) nonfat dry 
milk in PBS with 0.05% (wt:vol) Tween 20 (Millipore Sigma) (PBST) at room temperature for 
1 hour to block nonspecific binding, and overnight at 4° C with primary antibodies in 3% 
BSA (wt:vol) in PBST and finally with HRP-conjugated secondary antibody in blocking 
buffer. Blots were developed using the Western Lightning Plus-ECL enhanced 
chemiluminescence detection kit (PerkinElmer). Immunoblotting was performed with 
antibodies against TLR2 (Santa Cruz, sc-21760), TLR4 (Santa Cruz, sc-293072), MyD88 
(Santa Cruz, sc-74532), phospho-STAT3 (Cell Signaling, CS9145), STAT3 (Cell Signaling, 
CS12640), NLRP3 (LSBio, LS- C334192), FAS (Cell Signaling, #3180), ACC (Cell 
Signaling, #3662), ERK1/2 (Cell Signaling, #9102), Occludin (Santa Cruz, sc-271842) and 
Claudin 1 (Santa Cruz, sc- 166338). 
Glucose tolerance test 
Mice were transferred to clean cages with no food and fasted for approximately 12 hours 
with access to drinking water. A 20% glucose solution was i.p. injected (2 g/kg mouse body 
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mass) and small drops of blood were obtained from tail cuts and assessed for baseline 
glucose levels using a One-touch Ultra 2 (Lifescan, Johnson & Johnson) glucometer at 30, 
60, 90 and 120 minutes. 
Intestinal permeability 
Fecal albumin measurements were performed on dried fecal pellets using the Mouse 
Albumin ELISA Quantitation Set from Bethyl Laboratories according to manufacturer’s 
instructions. An in vivo permeability assay to assess barrier function was performed using 
the FITC-labeled dextran method. Food and water were withdrawn overnight, and mice 
were gavaged with 45 mg/100 g body weight of FITC-labeled dextran (FD-4; Sigma-
Aldrich). Serum was collected 5 hours after FD-4 gavage, and fluorescence intensity of 
each sample was measured (excitation, 492 nm; emission, 525 nm). Serum or plasma LPS 
concentrations were determined with the Mouse Lipopolysaccharides (LPS) ELISA Kit 
obtained from Cusabio following manufacturer’s instructions. 
Cytosolic acetyl-CoA measurement 
Frozen liver pieces were weighed, thawed, cut into smaller pieces and homogenized 
using a pestle in 1.5 ml microfuge tubes on ice. The cytoplasmic fraction was separated 
from the mitochondria and deproteinized using Mitochondria/Cytosol Fractionation Kit (Bio 
Vision, # K256) and Deproteinizing Sample Preparation Kit (Bio Vision, # K808), 
respectively. Acetyl-CoA concentrations were determined using PicoProbeTM Acetyl-CoA 
Assay Kit (Bio Vision, #K317). 
Intestinal organoid culture 
Intestinal crypts were isolated from MUP-uPA and gp130Act mouse colons and were 
cultured as described41. Two days after passaging, when the crypts started budding, the 
medium was changed to DMEM (Gibco, 11966-025) supplemented with 5 mM or 20 mM 
glucose or fructose or a combination of both sugars (5 mM glucose and 20 mM fructose) 
and 10% FBS. After changing the medium, the organoids were cultured for 24 hours. 
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RNA-seq analysis 
RNA was extracted from snap-frozen liver using the NucleoSpin® RNA kit (Macherey- 
Nagel) according to manufacturer’s instructions. Library preparation for RNA-seq was 
performed using TruSeq Stranded mRNA Library Prep Kit (Illumina) following 
manufacturer’s guidelines and best practices. For quality control of the libraries, the 
samples were inspected with a Bioanalyzer chip (DNA 1000, Agilent). Sequencing was 
performed for paired-end samples on a HiSeq 2500 v4.0 system. The resulting fastq files 
were quality controlled using FastQC, and adapters were trimmed using TrimGalore! v0.4.0 
(both developed at The Babraham Institute) for paired-end sequenced samples. The 
trimmed fastq files were aligned to the mouse reference genome 
(Mus_musculus.GRCm38.83) using STAR aligner (v2.5.1) 42. RSEM (v1.3.0)43 was used to 
estimate gene expression levels. Downstream analysis for differential gene expression of 
the raw count table was performed using DESeq244 in R. Heatmaps were drawn using the 
R package pheatmap (Pretty Heatmaps; R package version 1.0.10; https://CRAN.R-
project.org/package=pheatmap) clustering columns and rows and the values for each row 
being centered and scaled. Mapping of gene expression levels to corresponding KEGG 
pathways was performed using the R packages gage45 and path view46. 
Quantitative real-time PCR analysis 
RNA samples were prepared using RNeasy kit (Qiagen). RNA was reverse transcribed 
using a Super Script VILO cDNA synthesis kit (Thermo Scientific) and qPCR was performed 
using SYBR green (Biorad) based real-time PCR on a Biorad CFX96 machine. Relative 
mRNA expression was calculated from the comparative threshold cycle (Ct) values relative 
to ribosomal protein S18 mRNA. PCR primers were designed using online primer tools 
Primer3Plus and purchased from Integrated DNA Technologies. Primer sequences are 
provided in table S1. 
Microbiome analysis 
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Samples were processed following the Earth Microbiome Project47 DNA extraction and 
16S rRNA gene amplicon sequencing protocol, updated for the Kingfisher liquid-handling 
robot48. In brief, the 96-well MoBio Powersoil DNA kit was used to extract DNA from fecal 
samples and barcoded 515F-806R primers targeting the V4 region of the 16S rRNA were 
used for 16S amplification. Sequencing was performed at UCSD Institute for Genomic 
Medicine (IGM) on an Illumina MiSeq. 16S sequencing data were   uploaded to Qiita 
(https://qiita.ucsd.edu/) for QC, demultiplexing and processing with Deblur49. The resulting 
deblurred feature table was downloaded for analysis with QIIME  2 (https://qiime2.org) v 
2017.1050. The feature table was rarified to 8150 sequences per sample and the rarified 
table used for alpha diversity and beta diversity analysis. Taxonomic assignment was 
performed with QIIME 2 using a naive bayes sklearn classifier trained on the 515F/806R 
region of Greengenes 13_8 99% OTUs. 
D2O administration and measurement of de novo lipogenesis 
MUP-uPA and MUP-uPA/gp130Act mice were fed ad libitum CSD or HFrD for either 12 
weeks or 48 hours from 6-8 weeks of age. One day before termination, mice were i.p. 
injected with 0.028 ml/g body weight 0.9% NaCl D2O, and drinking water was replaced with 
6% D2O-enriched water. 19-20 hours later, plasma and tissue samples were immediately 
snap-frozen in liquid nitrogen. 
The 2H labeling of water from samples or standards was determined by deuterium 
acetone exchange. 5 μl of sample or standard were reacted with 4 μl of 10 M NaOH and 4 
μl of a 5% (vol:vol) solution of acetone in acetonitrile for 24 hours. Acetone was extracted 
by addition of 600 μl chloroform and 0.5 g Na2SO4 followed by vigorous mixing. 80 μl of the 
chloroform was then transferred to a glass GC–MS vial. Acetone was measured using an 
Agilent DB-35MS column (30 m x 0.25 mm i.d. x 0.25 μm, Agilent J&W Scientific) installed 
mass spectrometer (MS) with the following temperature program: 60° C initial, increase by 
20° C/min to 100° C, increase by 50° C/min to 220° C, and hold for 1 minute. The split ratio 
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was 40:1 with a helium flow of 1 ml/min. Acetone eluted at approximately 1.5 minutes. The 
mass spectrometer was operated in the electron impact mode (70 eV). The mass ions 58, 
59, and 60 were integrated and the percent M1 and M2 (m/z 59 and 60) calculated. Known 
standards were used to generate a standard curve and plasma percent enrichment was 
determined from this. All samples were analyzed in triplicate. In vivo calculation of the 
fraction of newly synthesized fatty acids (FNS) was based on the method described in51 
where FNS is described by the following equation: 𝐹𝐹𝐹𝐹𝐹𝐹 = 𝑀𝑀𝑀𝑀(𝑛𝑛×𝑝𝑝) where ME is the average 
number of deuterium atoms incorporated per molecule (ME = 1 × m1 + 2 × m2 + 3 × m3...), 
p is the deuterium enrichment in water and n is the maximum number of hydrogen atoms 







as described in51, where q is the fraction of hydrogen atoms and p + q = 1.  
GC–MS analysis of fatty acids and polar metabolites 
For tissue and plasma, total fatty acids were extracted from tissues and plasma using a 
Folch-based methanol/chloroform/saline extraction at a ratio of 1:2:1 with inclusion of 10 
nmol/mg [2H31]palmitate as a lipid internal standard as described previously52. Briefly, 250 μl 
methanol, 500 μl chloroform, 250 μl saline and isotope internal standards were added to 
~20 mg weighed tissue in a 2 mL Eppendorf. This was pulverized in a Retsch mill with 3 ball 
bearings for 5 minutes followed by removal of ball bearings and centrifugation at 21,000 g 
for 10 minutes. The lower chloroform phase was dried and then derivatized to form fatty 
acid methyl esters (FAMEs) via addition of 500 μl 2% H2SO4 in MeOH and incubation at 50° 
C for 2 hours. FAMEs were extracted via addition of 100 μl saturated salt solution and 2 
successive additions of 500 μl hexane and these were analyzed using a Select FAME 
column (100 m x 0.25 mm i.d.) installed in an Agilent 7890A GC interfaced with an Agilent 
5975C MS using the following temperature program: 80° C initial, increase by 20° C/min to 
170° C, increase by 1° C/min to 204° C, then 20° C/min to 250° C and hold for 10 minutes. 
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The percent isotopologue distribution of each fatty acid was determined and corrected for 
natural abundance. 
F1P analysis in liver and intestine 
Materials 
Optima LC/MS grade water was sourced from Fisher Scientific (Part number: W6-4). 
Pure HPLC ethyl alcohol was purchased from Sigma-Aldrich (Part number: 459828-2L). 
HPLC grade acetonitrile, methanol, and isopropyl alcohol were purchased from Honeywell 
(Part numbers: LC015-4, LC230-4, and LC323-4). 
Sample Prep            
Pre-weighed frozen tissue was transferred to a pre-chilled 2 mL homogenization tube 
containing 300 mg of 1 mm zirconium disruption beads. To each sample, a -20° C mixture 
of methanol:water (1:1) was added to achieve a normalized concentration of 50 µg of tissue 
per 1 µL of solvent. The samples were then homogenized using a BeadRuptor Elite 
homogenizer at a speed of 8 m/s for 3 cycles involving 10 seconds of homogenization 
followed by 10 seconds of dwell. The samples were then immediately placed on dry ice and 
the homogenate was transferred to clean 1.5 mL microfuge tubes and allowed to 
deproteinize for 30 minutes at -20° C. Samples were then centrifuged at a speed of 14,000 
rpm at 4° C for 10 minutes. 50 µL of each sample’s supernatant was then transferred to an 
amber autosampler vial containing a Wheaton 300 µL glass insert. Samples were stored in 
an Agilent Infinity 1290 UHPLC Autosampler maintained at 4° C until 20 µL of each sample 
was injected for targeted analysis by LC-MS/MS. 
LC-MS/MS Data Acquisition 
Chromatographic separation was performed on an Agilent Infinity 1290 UHPLC equipped 
with a Shodex HILICpak VT-50 2D Column (100 Å, 5 µm particle size, 2.0 x 150 mm, P/N 
SH-F7630400) maintained at a temperature of 60° C. Elution was performed with an 
isocratic elution of mobile phase containing 80:20 water:acetonitrile with 25 mM ammonium 
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formate at a constant flow rate of 0.250 mL/min over the course of 14 minutes. Data 
acquisition was performed on an Agilent 6495 Triple Quadrupole Mass Spectrometer 
equipped with an Agilent Jet Stream electrospray ionization source operating in negative 
mode under the following source settings: Gas Temp 200° C; Gas Flow 11 l/min; Nebulizer 
35 psi; Sheath Gas Temp 400° C; Sheath gas flow 11 l/min; Capillary voltage 3000 V; 
Nozzle Voltage 1500 V; High Pressure RF 50 V; Low Pressure RF 40 V. Fructose-1- 
phosphate was monitored using a single MRM with the following settings: 
In vivo treatment with LPS 
Six-week-old MUP-uPA and MUP-uPA/gp130Act mice were fed CSD or HFrD diet and i.p. 
injected daily with LPS (E. coli, Sigma Chemical, St. Louis, MO; 0.25 mg/kg) or vehicle 
(PBS). The mice were sacrificed after twelve weeks of treatment and the tissues were 
collected for further analysis. 
In vivo treatment with CCN1 
Recombinant CCN1 was purified as described53. Six-week-old MUP-uPA mice were fed 
HFrD for twelve weeks and i.p. injected with vehicle or 2 ug CCN1 in 200 μl of PBS every 
other day for the last four weeks of the experiment. The mice were sacrificed at 18 weeks of 
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Quantification and Statistical Analysis 
Data are presented either as means ± SEM or medians of continuous values and were 
analyzed by an unpaired two-sided Students’ t-test or Mann–Whitney test for comparison of 
two groups, respectively, followed by Benjamini-Hochberg FDR adjustment for P-values. 
Statistical significance is defined as a P-value greater than 0.05. Significance testing for 
differentially abundant bacteria was performed with the QIIME2 implementation of 
ANCOM54. 
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Figure Legends                                                                                                                                  
Figure 1. High-fructose diet induces hepatosteatosis and tumorigenesis. (a) MUP-uPA 
mice were fed CSD or HFrD. After 5 months, formalin-fixed, paraffin-embedded (FFPE) and 
frozen sections of non-tumor liver tissue were stained with H&E or Oil Red O (ORO) to 
reveal general histology and lipid droplets (n = 6 per group). Collagen deposition was 
visualized by Sirius Red staining of frozen sections. Scale bars, 100 μm. (b) Liver samples 
were also analyzed for total triglyceride (TG) content (n = 6), which is presented as fold- 
change relative to CSD-fed mice. (c) Liver morphology of CSD- and HFrD-fed MUP-uPA 
mice. (d) HCC development in CSD- or HFrD-fed MUP-uPA mice (n = 9). (e) HCC in DEN- 
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challenged BL6 mice fed CSD or HFrD (n = 9-11).Panels b,d and e show mean ± SEM 
asdetermined by two-sided Student’s t test, *P < 0.05, ***P < 0.001.                                                                                                             
Figure 2. HFrD induces inflammation, lipogenic gene expression and de novo 
lipogenesis. (a and b) Expression of lipogenic (a) and inflammatory (b) genes in MUP-uPA 
and DEN-challenged BL6 mice fed either CSD or HFrD for 5 months (n = 7-10). (c) 
Immunoblot (IB) analysis of ACC1 and FAS in livers of above MUP-uPA mice. (d) 
Measurement of newly synthesized fatty acids in livers of MUP-uPA mice using deuterated 
water (D2O) as a tracer (n = 7). Panels a,b and d show mean ± SEM determined by two 
sided Student’s t test,*P < 0.05, **P < 0.01, ***P < 0.001. 
Figure 3. Fructose causes barrier deterioration, decreased tight junction protein 
expression and ER stress. (a) Fecal albumin concentrations in MUP-uPA mice kept on 
CSD or HFrD or HFrD ± Abx (n = 6-7 per group). (b to c) Tight junction mRNAs in colonic 
(b) and jejunal (c) mucosa of CSD- or HFrD-fed (5 months) MUP-uPA mice (n = 7-9 per 
group). (d) Tight junction mRNAs in BL6 enteroids incubated with glucose (Glu) or fructose 
(Fru) (n = 4 per group). (e) Expression of inflammatory and ER stress markers in colonic 
mucosa of above mice (n=9) and a phspho-eIF2α blot of mucosal lysates. Panels a-e show 
mean ± SEM determined by two sided Student’s t test, *P < 0.05, **P < 0.01, ***P < 0.001. 
Figure 4. HFrD-induced upregulation of liver TLR and cytokine signaling and role of 
myeloid MyD88. (a) Heatmaps depicting differential expression of genes related to 
inflammation wound healing and innate immunity in livers of CSD- or HFrD-fed (5 months) 
MUP-uPA mice. (b) Expression of inflammatory chemokines and cytokines mRNAs in 
above mice. (c) IB analysis of TLRs, MyD88, phosphorylated and total STAT3 and NLRP3 
in livers of 6-month-old MUP-uPA mice fed CSD or HFrD or HFrD ± Abx for 5 months (n = 
7-9). (d and e) Expression of lipogenic and inflammatory genes (d) and IB analysis of 
ACC1 and FAS (e) in livers of Myd88Δmye and WT mice fed HFrD for 5 months (n = 8). (f) 
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Liver triglyceride content in above mice (n = 8; mg/g tissue).  Panels b,d and f show mean ± 
SEM determined by two-sided Student’s t test, *P < 0.05, **P < 0.01.     
Figure 5. Activated gp130 suppresses fructose-induced hepatic tumorigenesis, DNL 
and lipogenic and inflammatory gene expression. (a) HCC burden in CSD- or HFrD-fed 
MUP-uPA/gp130Act (MUP-uPA/Tg) mice and HFrD-fed MUP-uPA mice (n = 9 per group). (b) 
Liver lipogenic and inflammatory mRNAs in MUP-uPA/gp130Act mice fed CSD or HFrD and 
MUP-uPA mice fed HFrD (n = 9 per group). (c) Liver fatty acid synthesis in MUP-uPA and 
MUP-uPA/gp130Act mice administered D2O as a tracer (n=7 per group). (d to f) Control BL6 
mice and mice overexpressing the antimicrobial protein Reg3β in intestinal epithelial cells 
were fed CSD or HFrD for 3 months. (d) Frozen liver sections were ORO stained to reveal 
lipid droplets (n = 3 per group). Scale bars, 100 μm. (e) Relative mRNA amounts of liver 
lipogenic and inflammatory genes and (f) body weight in above mice (n = 4-5). Panels a-c 
and e-f show mean ± SEM determined by two-sided Student’s t test, *P < 0.05.  
Figure 6. TNF stimulates lipid droplet accumulation and lipogenic enzyme induction 
in human hepatocytes and schematic summary of the mechanism by which fructose 
intake stimulates hepatic DNL and steatosis. (a,b) Human hepatocytes isolated from two 
healthy donors were placed in sugar-free medium or in the presence of 5 mM fructose or 
glucose. LPS or TNF were added as indicated and 2 days later the cells were evaluated by 
ORO staining for lipid accumulation and qRT-PCR for DNL-related mRNAs (n=3; 
mean ± SEM by two- sided Student’s t test). (c) Schematic summary. In IEC dietary fructose 
is converted to F1P by KHK. F1P inhibits protein N-glycosylation triggering ER stress and 
intestinal inflammation to downregulate tight junction proteins (TJP) and trigger barrier 
deterioration and endotoxemia. Endotoxin (LPS) reaches the liver via the portal vein and 
engages TLR4 on macrophages to activate NF-κB via the adaptor protein MyD88 and 
induce TNF expression and secretion. TNF engages TNFR1 on hepatocytes to induce 
34  
caspase-2 (Casp2) mRNA whose translation is stimulated by ER stress-activated IRE1. 
Casp2 activates SREBP1 to induce ACC1 and FAS, thereby priming the liver to convert 














Extended Data Figure 1. HFrD stimulates HCC development without affecting body 
weight or white adipose tissue. (a) Food consumption by MUP- uPA and BL6 mice given 
CSD or HFrD (n = 9-12). (b) Formalin-fixed, paraffin-embedded (FFPE) and frozen liver tissue 
sections of DEN- challenged BL6 mice were stained with H&E or ORO (n = 6). Scale bars, 100 
μm. (c) Total triglyceride content in livers of DEN-challenged BL6 mice (n = 6) is presented as 
fold-change relative to CSD-fed mice. (d and e) Body and WAT weight of MUP-uPA (n = 9) 
(d) and DEN- challenged BL6 (n = 9-12 per group) (e) mice given CSD or HFrD were measured 
at the indicated time points. (f) Colon length in indicated mice (n = 9-12 per group). (g and h) 
MUP-uPA mice (n = 15 per group) (g) or DEN-challenged BL6 mice (n = 13-16 per group) (h) 
fed HFrD (▲) or CSD (■) for 5 months were subjected to glucose tolerance tests (GTT). (i and 
j) CSD- or HFrD- fed MUP-uPA mice (n = 4 per group) (i) or DEN-challenged BL6 mice (n = 6 
per group) (j) were placed in metabolic cages for two-and-a-half 24-hour cycles composed of 
two 12-hour light periods and three dark periods. VO2, VCO2, heat production and body 
weights were measured. (k) Non-fasting serum insulin was measured by ELISA in 
indicated mice (n=7-8). (l) Liver tumor histology in MUP-uPA and DEN-challenged BL6 
mice given either CSD, HFrD, or HFrD + Abx cocktail (n = 7-12). FFPE tumor sections were 
stained with hematoxylin and eosin (H&E). Scale bars, 100 μm. Unpaired two-sided Student’s 
t test was used in panels c to f and i to k, whereas Mann-Whitney test was used in panels g 
and h. Mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001.  
Extended Data Figure 2. Regulation of fructose-stimulated DNL and lipogenic enzymes. 
(a) Cytosolic acetyl-CoA concentrations in 6-month-old CSD and HFrD fed MUP- uPA mice (n 
= 7-9). (b) Expression of genes encoding FA-oxidizing enzymes in CSD- or HFrD- fed (5 
months) MUP-uPA and DEN-challenged BL6 mice (n = 7-10). (c) A metabolic chart comparing 
pathways through which glucose and fructose are converted to acetyl-CoA in the cytoplasm. 
GK-glucokinase; KHK-ketohexokinase; GI-glucose isomerase; PFK-phosphofructokinase. 
Cytoplasmic acetyl-CoA is converted to malonyl-CoA by acetyl-CoA carboxylase (ACC) and 
malonyl-CoA serves as the building block for synthesis of C16:0 (palmitate) and C18:0 
(stearate) by fatty acid synthase (FAS). Expression of ACC1 and FAS is strongly upregulated 
by prolonged HFrD feeding. (c and d) Measurement of newly synthesized FA in livers (d) and 
jejunum (e) of MUP-uPA mice using D2O as a tracer after a short-term feeding period (48 
hours; n = 7). (f) Amounts of F1P in liver and jejunum expressed in arbitrary units (48 hours 
feeding; n = 7). (g and h) Expression of inflammatory and lipogenic genes and ACC1 protein 
in livers (g) and fecal albumin and serum FITC-dextran concentrations (h) in CSD- or HFrD-
fed (48 hours) mice (n = 7). Unpaired two-sided Student’s t test was used in panels a, b and 
d-h. Mean ± SEM, *P < 0.05, **P < 0.01. 
Extended Data Figure 3. HFrD feeding causes downregulation of TJP, ER stress, colonic 
inflammation and barrier deterioration. (a and b) Expression of TJP genes in colon (a) and 
jejunum (b) of MUP- uPA mice fed HFrD with or without concomitant Abx treatment (n = 6-9). 
(c) IB analysis of indicated TJP in colon tissue of above mice (n = 7-9). (d) Expression of Il22 
mRNA and IL-22 regulated genes in colon tissue of CSD-, HFrD-, or HFrD + Abx-fed MUP- 
uPA mice (n = 7-9). (e and f) BL6 mice were given 30% fructose in drinking water or regular 
water and fed NCD for 5 (e) or 3 (f) months and mRNA amounts of TJP genes in colon and 
jejunum (e), colon length and FITC-dextran serum levels were measured (f). (g to h) BL6 mice 
were given 30% fructose or 30% sucrose in drinking water and fed NCD for 3 months and 
colon length and FITC-dextran serum levels (g), colon TJP mRNAs (h) and ER stress marker 
mRNAs (i) were measured. (j) Chop and sXbp1 mRNA amounts in fructose and glucose 
treated organoids (n=3). (j-m) Expression of indicated mRNAs in BL6 enteroids maintained in 
media containing the indicated glucose and/or fructose concentrations (mM) (n = 3-4) and 
treated with KHK inhibitor (k and l), TUDCA (m) or vehicle. Unpaired two-sided Student’s t test 
was used in all panels, other than c, to determine Mean ± SEM, *P < 0.05, **P < 0.01, ***P < 
0.001.  
Extended Data Figure 4. Fructose-induced alterations in the liver transcriptome. (a) KEGG 
pathway map of innate immune signaling with HFrD-induced genes indicated in red. (b) Heatmap 
depicting the entire transcriptome of non-tumor liver tissue from DEN-treated BL6 mice kept on 
CSD or HFrD for 5 months and analyzed immediately thereafter. (c) Heatmap depicting the entire 
transcriptome of tumor-bearing liver tissue from DEN-treated BL6 mice kept on CSD or HFrD until 
9 months old. (d) Heatmap depicting expression of HCC-related genes in non-tumor and tumor 
liver tissues from mice described in (b). The color code represents relative mRNA abundance 
where red shows overexpression and blue shows under expression. (e) Most significant Gene 
Ontology enrichment terms for Biological Pathways for the genes shown in heatmap (b) comparing 
DEN-treated BL6 mice fed a CSD or HFrD at 6 months of age. The bigger the dot, the more genes 
fall in the respective category. The color code represents the adjusted P-value (all are significant 
and below a cut-off level of 0.01) determined using Benjamini-Hochberg FDR adjustment. 
Extended Data Figure 5. Fructose-induced endotoxemia, hepatosteatosis, HCC, liver 
fibrosis, glucose intolerance and colonic inflammation are inhibited by antibiotics. (a) 
CSD and HFrD-fed MUP-uPA and DEN- challenged BL6 mice were treated or not with a broad-
spectrum Abx cocktail for 5 months, after which serum endotoxin concentrations were 
measured (n = 7-9). (b) HCC burden in MUP-uPA and DEN-challenged BL6 mice given HFrD 
alone or HFrD plus Abx cocktail (n=7-11). (c) Hepatosteatosis in MUP-uPA and DEN-
challenged BL6 mice given HFrD ± Abx for 5 months determined by ORO staining of liver 
sections. Scale bars, 100 μm. (d) Liver triglyceride content in above mice (n = 6). (e - g) 
Expression of lipogenic (e) and inflammatory (f) genes and IB analysis of liver ACC1 and FAS 
(g). (h, i) Liver F1P abundance (MUP-uPA; n = 7) (h) and cytosolic acetyl-CoA (n = 7-8; the 
HFrD bar is same as in Extended Data Figure 2a). (j, k) glucose tolerance (j) and non-fasting 
serum insulin (n=7) (k). (l) Total body and white adipose tissue weights in indicated mice (n=7-
12) (m) Liver fibrosis in HFrD-fed MUP-uPA mice was examined by Sirius Red staining (n = 
7). (n) Colon length in indicated mouse strains (n = 7-9; the HFrD bars are same as in 
Extended Data Figure 1f). Scale bars, 100 μm. Unpaired two-sided Student’s t test was used 
in panels a, b, d-f, h, I, k, l and n to determine mean ± SEM, whereas panel j was analyzed 
using a Mann-Whitney test. *P < 0.05, **P < 0.01, ***P < 0.001. 
  
Extended Data Figure 6. Antibiotics attenuate fructose-induced hepatosteatosis, barrier 
deterioration and other alterations in BL6 mice. (a to g) BL6 mice were fed CSD or HFrD 
± Abx. (a) After five months, liver tissue sections were stained with ORO (n = 9). Scale bars, 
100 μm. (b and c) Inflammatory and DNL-related mRNAs in liver were determined by Q-RT- 
PCR (n = 9). (d and e) Inflammatory and lipogenic proteins in liver lysates were analyzed by 
IB analysis (n = 9). (f and g) Q-RT-PCR analysis of indicated TJP genes in jejunum (f) and 
colon (g) (n = 9). Two-sided Student’s t test was used to determine mean ± SEM, *P < 0.05, 
**P < 0.01, ***P < 0.001. 
Extended Data Figure 7. Fructose drink enhances hepatosteatosis, expression of liver 
mRNAs encoding inflammatory cytokines and DNL-related enzymes and barrier 
deterioration. (a-c) BL6 mice were placed on 30% fructose in drinking water or regular water 
and NCD for 5 months (n = 8). (a) Liver sections were ORO stained. (b) mRNA amounts of 
liver inflammatory and DNL-related genes were PCR analyzed. (c) Total body, liver and white 
adipose tissue weights were measured. (d - h) BL6 mice placed on 30% fructose drink or 
regular water and HFD for 3 months. Body, liver and WAT weight and liver/body weight ratio 
were determined (n = 8). (d) Liver sections were analyzed by ORO staining. (e) Liver mRNAs 
encoding cytokines and DNL-related proteins were measured using Q-RT-PCR (n = 7) (f). 
Expression of TJP mRNAs in colon (n = 7) (g) and FITC-dextran in serum (n = 6) (h) were also 
measured. Scale bars, 100 μm. Two-sided Student’s t test was used to determine mean 
± SEM,*P < 0.05, **P < 0.01, ***P < 0.001.   
Extended Data Figure 8. Fructose-induced upregulation of YAP target genes and 
attenuation of TJP mRNA downregulation, barrier deterioration, hepatosteatosis and 
induction of DNL-related proteins in MUP-uPA/gp130Act and CCN1-treated mice. (a,b) 
Expression of indicated mRNAs in BL6 enteroids maintained in media containing the indicated 
glucose and fructose concentrations (mM) (n = 3) (a) and in colonic mucosa of MUP-uPA mice 
(n = 7-8) (b) was measured by Q-RT-PCR. (c) Enteroids from MUP-uPA and MUP- 
uPA/gp130Act mice (n = 4) were incubated with 20 mM fructose. Expression of indicated 
mRNAs was measured by Q-RT-PCR. (d and e) Expression of anti-microbial (d) and TJP  (e) 
mRNAs in colon tissues of MUP-uPA/gp130Act (MUP-uPA/Tg) mice fed CSD or HFrD 
compared to MUP-uPA mice fed HFrD for five months (n = 9). Asterisks indicate significant 
changes between MUP-uPA and MUP-uPA/Tg mice fed HFrD. (f) IB analysis of claudin-1 in 
colons of MUP-uPA/gp130Act and MUP-uPA mice kept on CSD or HFrD as indicated. (g) FITC-
dextran serum concentrations in indicated mice (n = 6). (h) Serum endotoxin concentrations 
in indicated mice measured by ELISA. (i) F1P abundance in liver and jejunum of indicated 
mice (arbitrary units; n = 7). (j to p) 6-week-old MUP-uPA mice were fed HFrD for 3 months 
and i.p. injected 2 µg CCN1 or vehicle (PBS) every other day for the last 4 weeks of HFrD 
feeding. Length (j) and TJP mRNA expression (k) were determined on excised colons (n = 7). 
Fecal albumin was measured by ELISA (n = 8) (l). ORO staining and triglyceride 
concentrations (n = 7) (m), inflammatory and lipogenic gene expression (n = 7) (n) and FAS 
protein amounts (n = 7) (o) were measured in liver tissue. (p) Body weight was measured at 
the end of the CCN1 treatment course (n = 7). (q) Endotoxin levels in serum of indicated mice 
(n=3) Scale bars, 100 μm. Two-sided Student’s t test was used to determine mean ± SEM, *P 
< 0.05, **P < 0.01, ***P < 0.001. 
 
Extended Data Figure 9. Low-dose LPS treatment stimulates hepatosteatosis and 
increases lipogenic and inflammatory gene expression and effect of fructose on 
microbiome diversity. (a to c) Six-week-old MUP- uPA mice were fed CSD and received 
daily i.p. injections of LPS (0.25 mg/kg) or vehicle (PBS) or were fed HFrD for 3 months. (a) 
ORO staining of liver sections (n = 8). (b) Liver triglyceride concentrations in above mice (n = 
7). (c) Q-RT-PCR analysis of lipogenic and inflammatory mRNAs (n = 8). (d to f) Six-week-old 
MUP-uPA/Tg mice were fed HFrD and received daily i.p. injections of LPS or PBS and 
compared to MUP-uPA mice that were fed HFrD only.(d) ORO staining of liver sections (n = 
8; scale bars, 100 μm). (e) Liver triglyceride concentrations (n = 7). (f) Relative mRNA amounts 
of lipogenic and inflammatory genes (n = 8). (g and i) Relative abundance of significantly 
differing taxa. Significance was determined by ANCOM. Box-plots of observed operational 
taxonomic units (OTUs) α-diversity indices comparing stool samples of MUP-uPA (g) and 
MUP-uPA/Tg (i) mice treated as indicated. (h and j) Principal coordinate analysis of 
microbiome data using unweighted UniFrac distances; difference between CSD and HFrD was 
significant in both MUP-uPA (h) (pseudo-F statistic = 2.88, P < 0.001, n = 10 and 24) and 
MUP-uPA/Tg (j) (pseudo-F statistic = 9.19, P < 0.001, n = 11 and 12) mice as determined by 
PERMANOVA. Two-sided Student’s t test was used in panels b,c,e and f to determine mean 
























Extended Data Table 1. Primer sequences 
 
 
Gene name Forward (5’ - 3’) Reverse (5’ - 3’) 
Acly CTGTGCCACCATGTTCTCCTC AGGCCTGGTTCTTGGCTACTG 
Acaca TTCCACGTAGGAGGAGCTTCC CCTCCGGTGCCTTCTCATTAC 
Fasn AGAAGAGCCATGGAGGAGGTG ATGTCCACACCACCAATGAGG 
Mlxipl CGGATACGGACTTGGAGGATC GAAGTGTCCGCTGTGGATGAC 
Srebf1 GATCAAAGAGGAGCCAGTGC TAGATGGTGGCTGCTGAGTG 
Emr1 GACTGACAACCAGACGGCTTG TCACTGCCTCCACTAGCATCC 
Tnf GCACAGAAAGCA TGACCCG  GCCCCCCA TCTTTTGGG  
Ccl2 GCCAGCTCTCTCTTCCTCCA  CCCAGAAGCA TGACAGGGAC  
Ccl5 AATCCCCTACTCCCACTCGG  TTCTTGGGTTTGCTGTGCAG  
Il1b  CAACCAACAAGTGATATTCTCCATG  GATCCACACTCTCCAGCTGCA  
Il6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA  
Cldn1 ATCACCTTCGGGAGCTCAGGT TGATGGGGGTCAAGGGGTCAT 
Cldn3 CTGGTCGGCCAACACCATCAT ATGGTTTGCCTGTCTCTGCCC 
Cldn4 GCAGAGCACAGGTCAGATGCA AGGGCAGGTCCTGGAGAATGT 
Cldn5 TGGACCACAACATCGTGACGG TGCCTCCCGCCCTTAGACATA 
Cldn6 CCCTTGGTGGCTGATGCTCAA AGGTGGAGCTTGGACTCAGGT 
Cldn7 AACATCATCACAGCCCAGGCC ATGTTTGGAGGTGGAGTGGCC 
Cldn8 GTGCTTGGTGGTGTTGGCATG CGTTGAGTGGTGCGATGGGAT 
Cldn9 AAGTGGTATGGGAGGGGCTGT CGCAGGTGGAAGCTTCTGGAA 
Cldn12 TGTGTGCAGATGTGCTCCTGT GCAGGAGGGCTTGAGCTGTAT 
Cldn13 GGCTCTTGGAATCCTGCATCT TGGCATCTGGGTCTGTCTCAT 
Cldn14 CTAACCAGAGGGCATGTGTGC AGTCCCATCCACCTTGATGCT 
Cldn19 GGAATTCTTCAACCCCAGCAC ATAGGGCTGTGGGATGCTGTT 
Ocln TCCGGATCCTGTCTATGCTCA ATAGCCACCTCCGTAGCCAAA 
Tjp1 GAAACTCTGCTGAGCCCCCTA GTTTTAGGGTCACCCGACGAG 
Tjp2 CGAAGCAGTCTGGGTCTCTGA CCGGCTCCTCTAGCTCATTGT 
Tjp3 ATGGTATGCCATTTCGGAACC CCGGGTACAACGTGTCCACTA 
Ctgf CAGAGTGGAGCGCCTGTTCTA AGGTGTCCGGATGCACTTTTT 
Ccne GTCTGCAAGATGCCTTGGATG CAACCTACAACACCCGAGCAG 
Reg3b ATGGCTCCTACTGCTATGCC GTGTCCTCCAGGCCTCTTT 
Reg3g ATGGCTCCTATTGCTATGCC GATGTCCTGAGGGCCTCTT 
Lcn2 ACATTTGTTCCAAGCTCCAGGGC CATGGCGAACTGGTTGTAGTCCG 
Il22 GGCCAGCCTTGCAGATAACA GCTGATGTGACAGGAGCTGA 
S100a9 GGTGGAAGCACAGTTGGCA GTGTCCAGGTCCTCCATGATG 
18s AGCCCCTGCCCTTTGTACACA  CGATCCGAGGGCCTCACTA  
